申请人:Taisho Pharmaceutical Co., Ltd.
公开号:EP2377851A1
公开(公告)日:2011-10-19
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.
由式(I)代表的化合物或其药学上可接受的盐具有抑制 CRTH2 的作用,因此可用于预防或治疗过敏性疾病,如哮喘、特应性皮炎和过敏性鼻炎。